Literature DB >> 19194279

Nonadenomatous dysplasia in barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study.

Rachel L Rucker-Schmidt1, Carissa A Sanchez, Patricia L Blount, Kumran Ayub, Xiahong Li, Peter S Rabinovitch, Brian J Reid, Robert D Odze.   

Abstract

Rarely, dysplasia in Barrett's esophagus (BE) is composed of crypts lined by cuboidal-shaped cells that contain a centrally located nucleus, markedly increased nuclear/cytoplasmic ratio, but without nuclear stratification characteristic of conventional "adenomatous" dysplasia. The aim of this study was to evaluate the clinical and pathologic features, natural history, and DNA content flow cytometric abnormalities of BE patients with non-adenomatous dysplasia (NAD) in a cohort of BE patients enrolled in a prospective surveillance program. Eighteen patients with NAD identified over a 6 year period, in a cohort of 270 consecutive patients with BE and without esophageal adenocarcinoma (EA) at baseline, were evaluated for clinical and pathologic features, including association with conventional adenomatous dysplasia and EA, DNA content flow cytometric abnormalities (tetraploidy and aneuploidy) and outcome, over a mean follow-up period of 4.1 years. The findings in the 18 study patients were compared to those in the 252 remaining (control) patients without NAD. Control patients included 228 with metaplasia/indefinite for dysplasia, and 24 with conventional adenomatous dysplasia (13 low-grade, 11 high-grade). The prevalence rate of NAD in our BE cohort was 6.7% Of the 18 study patients, there were 17 were males and 1 female of mean age 66.7 years. The mean length of BE was 3.9 cm NAD foci were associated with goblet or non-goblet epithelium in 62% and 38% of cases, respectively. Ninety-four percent of patients with NAD (17/18) also had conventional adenomatous dysplasia (four with low-grade, 13 with high-grade) elsewhere in the esophagus at the same endoscopic procedure as the one that detected NAD. Patients with NAD had a significantly shorter length of BE compared to control patients with conventional adenomatous dysplasia (N=24) (p=0.03). Patients with NAD also showed a significantly higher rate of DNA content flow cytometric abnormalities compared to the entire cohort of control patients (38% vs. 11%, p=0.05). However, no significant differences regarding either flow cytometric abnormalities or progression to EA were found when the NAD patients were compared only to the 24 controls with conventional adenomatous dysplasia. NAD is a high grade histologic variant of intraepithelial neoplasia that is episodic in nature, and shows a high association with conventional adenomatous high-grade dysplasia.

Entities:  

Mesh:

Year:  2009        PMID: 19194279      PMCID: PMC2702161          DOI: 10.1097/PAS.0b013e318198a1d4

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  20 in total

1.  Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables.

Authors:  P S Rabinovitch; G Longton; P L Blount; D S Levine; B J Reid
Journal:  Am J Gastroenterol       Date:  2001-11       Impact factor: 10.864

2.  Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.

Authors:  B J Reid; L J Prevo; P C Galipeau; C A Sanchez; G Longton; D S Levine; P L Blount; P S Rabinovitch
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

3.  Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets.

Authors:  B J Reid; D S Levine; G Longton; P L Blount; P S Rabinovitch
Journal:  Am J Gastroenterol       Date:  2000-07       Impact factor: 10.864

4.  Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.

Authors:  Massimo Conio; Sabrina Blanchi; Gabriella Lapertosa; Roberto Ferraris; Renato Sablich; Santino Marchi; Vittorio D'Onofrio; Teresa Lacchin; Gaetano Iaquinto; Guido Missale; Paolo Ravelli; Renzo Cestari; Giorgio Benedetti; Giuseppe Macrì; Roberto Fiocca; Francesco Munizzi; Rosangela Filiberti
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

5.  Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.

Authors:  E Montgomery; J R Goldblum; J K Greenson; M M Haber; L W Lamps; G Y Lauwers; A J Lazenby; D N Lewin; M E Robert; K Washington; M L Zahurak; J Hart
Journal:  Hum Pathol       Date:  2001-04       Impact factor: 3.466

6.  The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma.

Authors:  Carlo C Maley; Patricia C Galipeau; Xiaohong Li; Carissa A Sanchez; Thomas G Paulson; Patricia L Blount; Brian J Reid
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

7.  Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus.

Authors:  R C Haggitt; J Tryzelaar; F H Ellis; H Colcher
Journal:  Am J Clin Pathol       Date:  1978-07       Impact factor: 2.493

8.  Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications.

Authors:  R H Riddell; H Goldman; D F Ransohoff; H D Appelman; C M Fenoglio; R C Haggitt; C Ahren; P Correa; S R Hamilton; B C Morson
Journal:  Hum Pathol       Date:  1983-11       Impact factor: 3.466

9.  Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus.

Authors:  Carlo C Maley; Patricia C Galipeau; Xiaohong Li; Carissa A Sanchez; Thomas G Paulson; Brian J Reid
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

10.  Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma.

Authors:  Kaiyo Takubo; Junko Aida; Yoshio Naomoto; Motoji Sawabe; Tomio Arai; Hiroaki Shiraishi; Masaaki Matsuura; Christian Ell; Andrea May; Oliver Pech; Manfred Stolte; Michael Vieth
Journal:  Hum Pathol       Date:  2008-08-27       Impact factor: 3.466

View more
  8 in total

Review 1.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

Review 2.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

3.  Overdiagnosis of high-grade dysplasia in Barrett's esophagus: a multicenter, international study.

Authors:  Nikhil A Sangle; Shari L Taylor; Mary J Emond; Michelle Depot; Bergein F Overholt; Mary P Bronner
Journal:  Mod Pathol       Date:  2015-02-13       Impact factor: 7.842

Review 4.  [Intraepithelial neoplasia of Barrett's esophagus: prognosis of potential malignancy].

Authors:  M Werner; S Lassmann
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

5.  The transcription factor MIST1 is a novel human gastric chief cell marker whose expression is lost in metaplasia, dysplasia, and carcinoma.

Authors:  Jochen K M Lennerz; Seok-Hyung Kim; Edward L Oates; Won Jae Huh; Jason M Doherty; Xiaolin Tian; Andrew J Bredemeyer; James R Goldenring; Gregory Y Lauwers; Young-Kee Shin; Jason C Mills
Journal:  Am J Pathol       Date:  2010-08-13       Impact factor: 4.307

6.  Loss of cell polarity protein Lgl2 in foveolar-type gastric dysplasia: correlation with expression of the apical marker aPKC-zeta.

Authors:  Mikhail Lisovsky; Fumihiro Ogawa; Karen Dresser; Bruce Woda; Gregory Y Lauwers
Journal:  Virchows Arch       Date:  2010-10-13       Impact factor: 4.064

7.  Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma.

Authors:  Takehiro Tanaka; Atsushi Fujimura; Koichi Ichimura; Hiroyuki Yanai; Yasuharu Sato; Katsuyohi Takata; Hiroyuki Okada; Seiji Kawano; Shunsuke Tanabe; Tadashi Yoshino
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

Review 8.  Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression.

Authors:  Ksenia S Maslyonkina; Alexandra K Konyukova; Darya Y Alexeeva; Mikhail Y Sinelnikov; Liudmila M Mikhaleva
Journal:  Cancer Med       Date:  2021-12-06       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.